The 2009 san antonio breast cancer symposium

Clinical Breast Cancer

Volumn 10, Issue 1, 2010, Pages 19-26

  Abair, Tristin ^a   Garcia, Kristin ^a   Quill, Timothy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ALOPECIA; ANEMIA; ARTHRALGIA; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOT FLUSH; HUMAN; HYPERTENSION; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; MENOPAUSE; METASTASIS; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NONHUMAN; PREMENOPAUSE; PROTEINURIA; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 76949098605     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.002     Document Type: Conference Paper

References (31)

1. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008; 26:798-805.
2. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14:2738-2746
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717
4. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intentionto- treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008; 26:1965-1971
5. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271
6. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26:1948-1955
7. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008; 26:1956-1964
8. Goss PE, Ingle JN, Martino S, et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. Paper presented at: the 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 13. Available at: http:// www.sabcs.org. Accessed: December 15, 2009.
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
10. Miles DW, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, doubleblind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Research 2009; 69(suppl):495s (abstract 41).
11. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2- negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27(15 suppl):42s (abstract 1005).
12. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799
13. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: a randomized, double-blind, placebocontrolled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2- negative metastatic breast cancer. Cancer Research 2009; 69(suppl):495s (abstract 42).
14. Nahta R, Yu D, Hung M-C, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Prac Oncol 2006; 3:269-280
15. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-1639
16. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28:803-814
17. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008; 26:3317-3323
18. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008; 26(15 suppl):44s (abstract 1015).
19. Blackwell K, Burstein H, Sledge G, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Paper presented at: the 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 61. Available at: http://www.sabcs.org. Accessed: December 30, 2009.
20. ClinicalTrials.gov [Web site]. A randomised, multicentre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00490139. Accessed: October 23, 2008.
21. Perez E, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2- positive breast cancer. J Clin Oncol 2007; 25(18 suppl):6s (abstract 512).
22. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC?T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC?TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Research 2009; 69(suppl 3):500s (abstract 62).
23. Smith I, Procter M, Gelber RD, et al. 2-year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
24. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008; 8:324-333
25. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Paper presented at: the 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 80.
26. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009; 69(suppl 3): (abstract 80).
27. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC - T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Paper presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-7, 2006; San Antonio, TX. Abstract 52. Available at: http://www.abstracts2view.com/sabcs06/view. php?nu=SABCS06L-78. Accessed: December 16, 2008.
28. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-749
29. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96:759-769
30. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792
31. ClinicalTrials.gov [Web site]. A multicenter phase III randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk nodenegative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab. Available at: http://clinicaltrials. gov/ct2/show/NCT00625898. Accessed: January 12, 2010.